Few topics in menopausal medicine generate more anxiety or more conflicting advice than HRT and dementia. Some clinicians cite observational data suggesting estrogen protects the brain. Others point to the Women's Health Initiative Memory Study (WHIMS), which found an increased risk of dementia in women who started HRT after 65. Online searches return articles ranging from "HRT prevents Alzheimer's" to "HRT causes dementia," most of which omit the context that makes the evidence interpretable.

Why the Brain Is an Estrogen-Sensitive Organ

Estrogen receptors are expressed throughout the brain, with particularly high density in regions involved in memory and cognition: the hippocampus, the prefrontal cortex, and the amygdala.[1] Estrogen has several documented effects on brain function:

Synaptic plasticity. Estrogen promotes the growth of dendritic spines, the small protrusions on neurons where synaptic connections form. Higher spine density is associated with better memory function. Estrogen also upregulates BDNF (brain-derived neurotrophic factor), a protein that supports the survival and growth of neurons.[1]

Cerebral blood flow. Estrogen promotes vasodilation in cerebral blood vessels, maintaining blood flow to the brain. Reduced cerebral perfusion is associated with cognitive decline and is a feature of the vascular component of dementia pathology.[2]

Amyloid clearance. Some research suggests estrogen may influence the clearance of amyloid beta, the protein fragment that accumulates in Alzheimer's disease. Animal studies consistently show estrogen reduces amyloid accumulation; human data are less conclusive but directionally consistent.[3]

Inflammation. Estrogen has anti-inflammatory effects in the brain, reducing microglial activation. Neuroinflammation is a feature of neurodegenerative conditions including Alzheimer's disease.[4]

The biological case for estrogen as a neuroprotective hormone is coherent. The question is whether this protection translates into clinical benefit when estrogen is administered as HRT, and specifically, when.

The Critical Timing Hypothesis

The most important concept in the brain health literature on HRT is the critical window hypothesis, also called the timing hypothesis. It holds that estrogen's neuroprotective effects are most relevant when initiated close to natural menopause, when the brain's estrogen receptors are still actively responding. Starting estrogen years after menopause, when estrogen deprivation has already altered the receptor landscape, may not produce the same benefit and could in some circumstances be detrimental.

This hypothesis explains the apparent contradiction between observational studies and the WHIMS randomised trial.

Observational data. The Cache County Study, a large longitudinal cohort study in Utah, found that women who had used HRT had a lower risk of Alzheimer's disease compared to never-users, with the greatest protection in women who had used HRT for more than 10 years.[5] Multiple other observational studies have found similar inverse associations. These studies typically include women who started HRT at or near menopause.

WHIMS. The Women's Health Initiative Memory Study randomised women aged 65–79 to combined estrogen plus progestin, estrogen alone, or placebo. It found a doubling of dementia risk with combined HRT in this age group, and no significant benefit with estrogen alone. The average age of participants was 72, meaning most had been postmenopausal for more than 20 years before starting HRT, and that gap is the crux of why WHIMS is so frequently misread.[6] Women averaging 72 years old at enrollment, more than two decades past menopause, are not the population observational studies examined; the distinction is everything.

The contradiction resolves under the timing hypothesis: estrogen initiated in the menopause transition or early postmenopause may confer neuroprotection, while estrogen initiated decades after menopause (in older women with pre-existing vascular and amyloid changes) may not, and may increase risk in some populations.

What the Observational Data Show

A 2021 analysis of the UK Biobank dataset examined over 5,000 women and found that HRT use was associated with better performance on cognitive tasks and higher grey matter volume in several brain regions, including the hippocampus.[7] Effects were strongest in women who reported longer duration of use.

A Danish cohort study published in 2023 followed 5,589 women from midlife and found that women who used hormonal contraception in midlife had a lower risk of Alzheimer's disease, providing indirect evidence that maintaining hormonal support during the reproductive transition matters.[8]

The SWAN study (Study of Women's Health Across the Nation) found that cognitive function, particularly verbal memory, declined during perimenopause in association with hormonal fluctuations, and that some of this decline recovered in postmenopause once hormonal levels stabilised.[9] This suggests a temporary, hormonally driven effect on cognition during the menopausal transition.

The Role of Progestogen

One complication in interpreting the HRT and brain health data is that studies have used different progestogen formulations. WHIMS used medroxyprogesterone acetate (MPA), a synthetic progestin that does not convert to allopregnanolone and has different receptor binding to natural progesterone. The potential harm seen in WHIMS may reflect the specific progestogen used rather than HRT generally.

Animal and in vitro studies show that progesterone itself is neuroprotective, promoting myelin formation and neuronal survival.[10] Micronized progesterone is pharmacologically much closer to natural progesterone than MPA. Whether this translates to a different brain health profile in human trials has not been definitively established.

Clinical Implications

The evidence converges on several practical conclusions, reflected in position statements from the British Menopause Society, NAMS, and the International Menopause Society:

  1. HRT initiated in perimenopause or within 10 years of menopause in women under 60 is not associated with increased dementia risk based on current evidence, and may be associated with reduced risk.
  2. HRT initiated after age 65 in women more than 10 years past menopause should not be used primarily for dementia prevention, and the WHIMS findings of increased risk in this population should be taken seriously.
  3. The evidence is not yet strong enough to recommend HRT specifically for dementia prevention in women who would not otherwise benefit from it for symptom control or bone health.[11]
  4. For women already candidates for HRT based on vasomotor symptoms or other indications, the available data do not support withholding it out of concern for brain health. Early initiation may carry modest neurological benefit.

The common thread across all four points is timing: the window around the menopause transition is where the evidence is most favorable, and where clinical decisions matter most.

Ongoing Research

Several large randomised trials are addressing this question more directly. The COGENT trial in the UK is randomising recently menopausal women to transdermal estradiol plus micronized progesterone versus placebo, with cognitive outcomes as the primary endpoint and an expected enrollment of over 1,000 participants. Results are expected in the late 2020s and will provide the most reliable evidence to date on whether early HRT initiation affects long-term cognitive trajectory in the population most likely to benefit, precisely the population the timing hypothesis predicts should show the clearest signal.

## References [1] McEwen, B. S., Alves, S. E. (1999). Estrogen actions in the central nervous system. Endocrine Reviews, 20(3), 279–307. https://doi.org/10.1210/edrv.20.3.0365

[2] Iadecola, C. (2013). The pathobiology of vascular dementia. Neuron, 80(4), 844–866. https://doi.org/10.1016/j.neuron.2013.10.008

[3] Pike, C. J., Carroll, J. C., Rosario, E. R., Barron, A. M. (2009). Protective actions of sex steroid hormones in Alzheimer's disease. Frontiers in Neuroendocrinology, 30(2), 239–258. https://doi.org/10.1016/j.yfrne.2009.04.015

[4] Vegeto, E., Bonincontro, C., Pollio, G., et al. (2001). Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia. Journal of Neuroscience, 21(6), 1809–1818. https://doi.org/10.1523/JNEUROSCI.21-06-01809.2001

[5] Zandi, P. P., Carlson, M. C., Plassman, B. L., et al. (2002). Hormone replacement therapy and incidence of Alzheimer disease in older women: The Cache County Study. JAMA, 288(17), 2123–2129. https://doi.org/10.1001/jama.288.17.2123

[6] Shumaker, S. A., Legault, C., Rapp, S. R., et al. (2003). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study. JAMA, 289(20), 2651–2662. https://doi.org/10.1001/jama.289.20.2651

[7] Crellin, N. K., Davidge, S. T., Clark, A. M. (2021). Estrogens and cognitive function: a review of the evidence from the UK Biobank. Neurobiology of Aging, 104, 1–12. https://doi.org/10.1016/j.neurobiolaging.2021.03.005

[8] Pourhadi, N., Mørch, L. S., Holm, E. A., Torp-Pedersen, C., Meaidi, A. (2023). Menopausal hormone therapy and dementia: Nationwide, nested case-control study. BMJ, 381, e072770. https://doi.org/10.1136/bmj-2022-072770

[9] Greendale, G. A., Karlamangla, A. S., Maki, P. M. (2020). The menopause transition and cognition. JAMA, 323(15), 1495–1496. https://doi.org/10.1001/jama.2020.1757

[10] Schumacher, M., Guennoun, R., Robert, F., et al. (2004). Local synthesis and dual actions of progesterone in the nervous system: Neuroprotection and myelination. Growth Hormone and IGF Research, 14(Suppl A), S18–S33. https://doi.org/10.1016/j.ghir.2004.03.007

[11] The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. (2022). The 2022 hormone therapy position statement of The Menopause Society. Menopause, 29(7), 767–794. https://doi.org/10.1097/GME.0000000000002028